MAKO Surgical (Nasdaq: MAKO) reported earnings on May 7. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), MAKO Surgical whiffed on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly and GAAP loss per share increased.

Margins improved across the board.

Revenue details
MAKO Surgical reported revenue of $19.6 million. The eight analysts polled by S&P Capital IQ looked for a top line of $23.6 million on the same basis. GAAP reported sales were 51% higher than the prior-year quarter's $13.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.28. The nine earnings estimates compiled by S&P Capital IQ forecast -$0.20 per share. GAAP EPS were -$0.28 for Q1 versus -$0.27 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 72.1%, 350 basis points better than the prior-year quarter. Operating margin was -59.9%, 2,490 basis points better than the prior-year quarter. Net margin was -59.7%, 2,470 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $27.7 million. On the bottom line, the average EPS estimate is -$0.22.

Next year's average estimate for revenue is $127.4 million. The average EPS estimate is -$0.56.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 911 members out of 943 rating the stock outperform, and 32 members rating it underperform. Among 240 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 230 give MAKO Surgical a green thumbs-up, and 10 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MAKO Surgical is outperform, with an average price target of $42.25.

Over the decades, small-cap stocks like MAKO Surgical have produced market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.